Hormone receptors as a marker of poor survival in epithelial ovarian cancer-Reference-Cited by-同舟云学术

Hormone receptors as a marker of poor survival in epithelial ovarian cancer

Published:2015-09 Issue:3 Volume:138 Page:634-639
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

van Kruchten Michel,van der Marel Pauline,de Munck Linda,Hollema Harry,Arts Henriette,Timmer-Bosscha Hetty,de Vries Elisabeth,Hospers Geke,Reyners Anna

Funder

Dutch Cancer Society

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference35 articles.

1. Vintage 2009 Populations;SEER Cancer Statistics Review,1975

2. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer;Elattar;Gynecol. Oncol.,2012

3. 17β-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer;Laviolette;Endocrinology,2010

4. Postmenopausal hormone use and incident ovarian cancer: associations differ by regimen;Hildebrand;Int. J. Cancer,2010

5. A phase II study of flutamide in ovarian cancer;Vassilomanolakis;Oncology,1997

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nuclear receptors in ovarian cancer: changing paradigms in cancer therapeutics;Frontiers in Oncology;2024-07-15

2. Postoperative Hormone Replacement Therapy and Survival in Women with Ovarian Cancer;Cancers;2022-06-23

3. Impact of estrogen receptor expression on prognosis of ovarian cancer according to antibody clone used for immunohistochemistry: a meta-analysis;Journal of Ovarian Research;2022-05-24

4. Genetic variation in progesterone receptor gene and ovarian cancer risk: A case control study;Gene;2022-04

5. Estrogen Receptor-Beta2 (ERβ2)–Mutant p53–FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC);Cancers;2022-02-22